UPOTREBA PSIHOAKTIVNIH SUPSTANCI U REGIONALNOM METADONSKOM CENTRU U SRBIJI

Tamara Popović; Aleksandra Dickov; Vladimir Knežević; Svetlana Ivanović Kovačević; Božana  Nikolic

Tamara Popović Klinika za psihijatriju, Univerzitetski Klinički centar Vojvodine; Novi Sad, Srbija
Aleksandra Dickov Klinika za psihijatriju, Univerzitetski Klinički centar Vojvodine, Novi Sad, Srbija; Univerzitet u Novom Sadu, Medicinski fakultet, Katedra za psihijatriju i psihološku medicinu; Novi Sad, Srbija
Vladimir Knežević Klinika za psihijatriju, Univerzitetski Klinički centar Vojvodine, Novi Sad, Srbija; Univerzitet u Novom Sadu, Medicinski fakultet, Katedra za psihijatriju i psihološku medicinu, Novi Sad, Srbija
Svetlana Ivanović Kovačević Klinika za psihijatriju, Univerzitetski Klinički centar Vojvodine, Novi Sad, Srbija; Univerzitet u Novom Sadu, Medicinski fakultet, Katedra za psihijatriju i psihološku medicinu, Novi Sad, Srbija
Božana Nikolic Katedra za farmaciju, Medicinski fakultet u Novom Sadu, UNiverzitet u Novom Sadu, Novi Sad, Srbija; Dom zdravlja Novi Sad, Novi Sad, Srbija

Ključne reči: metadonska supstituciona terapija, psihoaktivne supstance, prevalencija, ASSIST skor, rizik od zavisnosti

Sažetak

Uvod: Pacijenti na metadonskoj supstitucionoj terapiji (MST) često upotrebljavaju psihoaktivne supstance (nikotin, alkohol, kanabis, kokain, amfetamin i slične stimulanse, sedative, hipnotike, halucinogene i dr.), što može negativno uticati na terapijske ishode. Cilj ovog istraživanja je bio da se odredi prevalencija i modeli upotrebe psihoaktivnih supstanci kod pacijenata koji su na MST.

Metode: Istraživanje je sprovedeno u Metadonskom centru Univerzitetskog kliničkog centra Vojvodine u periodu avgust - oktobar 2022. godine. Podaci su prikupljeni pomoću opšteg i ASSIST (engl. The Alcohol, Smoking and Substance Involvement Screening Test) upitnika. Deskriptivna statistika je korišćena za analizu prikupljenih podataka.

Rezultati: Ukupno, 60 pacijenata na MST je uključeno u istraživanje. Među njima, bilo je najviše korisnika nikotina (98,3%), a zatim alkohola (10,0%) i nelegalnih psihoaktivnih supstanci (kanabisa, kokaina i meskalina) (5,1%) unutar tri meseca koja su prethodila istraživanju. Upotreba nelegalnih psihoaktivnih supstanci je uglavnom bila povremena. Tri pacijenta su imala ASSIST skor >27, što je ukazivalo na visok rizik od razvoja zavisnosti, alkoholne (2 pacijenta) ili kanabionoidne (1 pacijent).

Zaključak: Istraživanje je ukazalo na značajnu razliku u učestalosti upotrebe legalnih i nelegalnih psihoaktivnih susptanci. Zbog toga bi njihovu upotrebu trebalo pratiti na osnovu redovne i povremene analize urina.

Reference

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2023: Trends and Developments. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2023. (Available at https://www.emcdda.europa.eu/publications/european-drug-report/2023_en)

Lim J, Farhat I, Douros A, Panagiotoglou D. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. PLoS One. 2022; 31;17(3): e0266142. doi: 10.1371/journal.pone.0266142.

McBrien H, Luo C, Sanger N, Zielinski L, Bhatt M, Zhu XM, et al. Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. CMAJ Open. 2019;7(4): E665-E673. doi: 10.9778/cmajo.20190026

Charoensakulchai S, Onwan M, Kanchanasurakit S, Flaherty G, Matsee W. Recreational substance use among international travelers. J Travel Med. 2024: taae012. doi: 10.1093/jtm/taae012.

Scott TM, Arnsten J, Olsen JP, Arias F, Cunningham CO, Mindt MR. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs. Addict Sci Clin Pract 2021;16(1):64. doi: 10.1186/s13722-021-00272-4.

Custodio L, Malone S, Bardo MT, Turner JR. Nicotine and opioid co-dependence: Findings from bench research to clinical trials. Neurosci Biobehav Rev. 2022; 134:104507. doi: 10.1016/j.neubiorev.2021.12.030.

Le TA, Pham DTT, Quek TTC, Vu GT, Hoang CL, Tran TT, et al. Polysubstance Use among Patients Enrolling in Methadone Maintenance Treatment Program in a Vietnam Province with Drug-Driven HIV Epidemic. Int J Environ Res Public Health. 2019;16(18):3277. doi: 10.3390/ijerph16183277

Soyka M. Alcohol Use Disorders in Opioid Maintenance Therapy: Prevalence, Clinical Correlates and Treatment. Eur Addict Res. 2015;21(2):78-87. doi: 10.1159/000363232

Kleykamp BA, Vandrey RG, Bigelow GE, Strain EC, Mintzer MZ. Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers. Am J Drug Alcohol Abuse. 2015;41(3):251-6. doi: 10.3109/00952990.2014.987348.

Heikman PK, Muhonen LH, Ojanpera A. polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. BMC Psychiatry. 2017:17(1):245. doi: 10.1186/s12888-017-1415-y.

Le NT, Khuong QL, Vu TTV, Thai TT, Le HTCH, Dao PT, et al. Prevalence of Amphetamine-Type Stimulant Use and Related Factors among Methadone Maintenance Patients in Ho Chi Minh City Vietnam: A Cross-Sectional Study. J Psychoactive Drugs. 2021;53(4):355-363. doi: 10.1080/02791072.2020.1871126.

Tran BX, Ohinmaa A, Mills S, Duong AT, Nguyen LT, Jacobs P, et al. Multilevel predictors of concurrent opioid use during methadone maintenance treatment among drug users with HIV/AIDS. PLoS One. 2012;7(12): e51589. doi: 10.1371/journal.pone.0051569.

Lin C, Cao X, Li L. Psychoactive Substance Use among Methadone Maintenance Therapy Clients in China. Ment Health Addict. 2017;15(4):801-11. doi: 10.1007/s11469-017-9758-7

Ngarachu EW, Kiburi SK, Owiti FR, Kangethe R. The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya. Subst Abuse Treat Prev Policy. 2022; 17:12. doi: 10.1186/s13011-022-00437-7

Alías-Ferri M, Pellegrini M, Marchei E, Pacifici R, Rotolo MC, Pichini S, et al. New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. Biology (Basel). 2022;11(5):645. doi: 10.3390/biology11050645.

Vučković N, Dickov A, Коvačević M, Simonović P, Nikolić M, Jovanović M, et al. Supstituciona terapija zavisnika od opijata. Izmena i dopuna nacionalnioh smernica. Beograd: Ministarstvo zdravlja Republike Srbije, Republička stručna komisijaza prevenciju i kontrolu bolesti zavisnosti; 2012.

Verster A, Bunning E. Metahdone Guidelines. Project European Commission; 2000. Dostupno na: https://www.q4q.nl/euromethwork/home/publications/methadone-guidelines

World Health Organization. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Geneva: World Health Organization; 2010. (https://www.afro.who.int/ publications/alcohol-smoking-and-substance-involvement-screening-test-assist)

Kandel ER, Kandel DB. A Molecular Basis for Nicotine as a Gateway Drug. N Engl J Med. 2014; 371(21):932-43. doi: 10.1056/NEJMsa1405092

Ren M, Lotfipour S. Nicotine Gateway Effects on Adolescent Substance Use. West J Emerg Med. 2019; 20(5):696-709. doi: 10.5811/westjem.2019.7.41661

Reed ZE, Wootton RE, Munafo MR. Using Mendelian Randomization to Explore the Gateway Hypothesis: Possible Causal Effects of Smoking Initiation and Alcohol Consumption on Substance Use Outcomes. Addiction. 2022; 117(3):741-50. doi: 10.1111/add.15673

de Dios MA, Bradley JA, Caviness CM; Stein MD. Early Quit Days Among Methadone-Maintained Smokers in a Smoking Cessation Trial. Nicotine Tob Res. 2014;16(11):1463-9. doi: 10.1093/ntr/ntu099.

Bureau of Justice Assistance. Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP). Polysubstance Use Among People Who Use Opioids. Washington, DC 20531: U.S. Department of Justiceꞌs Office of Justice Programs; 2021. (Available at: https://www.cossup.org) doi: 10.2810/161905

Hammond D, Wadsworth E, Reid JL, Burkhalter R. Prevalence and modes of cannabis use among youth in Canada, England, and the US, 2017 to 2019. Drug Alcohol Depend. 2021; 219: 108505. doi: 10.1016/j.drugalcdep.2020.108505

Cui Y, LoParco CR, Bar-Zeev Y, Duan Z, Levine H, Abroms LC, et al. Theory-based correlates of cannabis use and intentions among US and Israeli adults: a mixed methods study. Subst Abuse Treat Prev Policy. 2023;18(1):54. doi: 10.1186/s13011-023-00562-x.

Chun J. Public Health Threat of Tobacco and Substance Use in Asia: An Introduction to the Theme Issue. J Psychoactive Drugs. 2020; 52(1):1-4. doi: 10.1080/02791072.2020.1717686.

Condelli WS, Fairbank JA, Dennis ML, Rachel JV. Cocaine Use by Clients in Methadone Programs: Significance, Scope, and Behavioral Interventions. J Subst Abuse Treat. 1991;8(4):203-12. doi: 10.1016/0740-5472(91)90040-h.

Roux P, Lions C, Vilotitch A, Michel L, Mora M, Maradan G, et al. Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study). Harm Reduct J. 2016; 13:12. doi: 10.1186/s12954-016-0100-7.

Khalili P, Nadimi AE, Baradaran HR, Janani L, Rahimi-Movaghar A, Rajabi Z, et al. Validity of self-reported substance use: research setting versus primary health care setting. Subst Abus Treat Prev Policy 2021;16(1):1-13. doi: 10.1186/s13011-021-00398-3.

Tran BX, Nguyen HLT, Le QNH, Mai HT, Ngo C, Hoang CD, et al. Alcohol and tobacco use among methadone maintenance patients in Vietnamese rural mountainside areas. Addict Behav Rep. 2017; 7:19-25. doi: 10.1016/j.abrep.2017.11.005.

Do HP, Nguyen LH, Nguyen NPT, Ngo C, Nguyen HLT, Le GT, et al. Factors associated with nicotine dependence during methadone maintenance treatment: findings from a multisite survey in Vietnam. BMJ Open. 2017:7(7): e015889. doi: 10.1136/bmjopen-2017-015889.

Ritter JM, Flower R, Henderson G, Loke YK, MacEwan, Rang HP. Rang & Dale's. Pharmacology. Ninth Edition. Elsevier; 2020.